Dermatology

These findings were the result of a new analysis of the inflammatory characteristics associated with the efficacy sustenance of biologic medications for psoriasis.

These findings, while reassuring for JAK inhibitor prescription, nonetheless suggest that VTE-related recommendations for prescriptions should be maintained.

These findings indicate that lower ambient solar radiation is linked with more frequent systemic psoriasis therapy.

Test your knowledge below on pooled data from ADvocate1 and ADvocate2 trials and stay up to date with the latest clinical advancements in atopic dermatitis treatment.

In this literature review, investigators concluded that subcutaneous injections of methotrexate have some advantages over oral therapy.

In this review of March 2025 in dermatology news, we highlight a variety of notable stories covered in the field regarding pipeline news and recent data.

These data on patients in Japan demonstrate positive efficacy and safety findings in real-world settings, with uniquely positive results among bio-naïve patients.

In this analysis, links between psoriasis and metabolic and cardiovascular risk were evaluated along with correlations between biomarkers and severity.

Pulse oximeter bias was less negative in darkly pigmented skin, suggesting a difference in performance across skin pigment categories.

These findings result from a systematic review and meta-analysis looking at the utilization of dupilumab among children and adolescents with atopic dermatitis.

These data point to the role of environmental factors in the development of atopic dermatitis and indicate targeted prevention strategies for those known to be impacted.

In this analysis, the investigators evaluated the temporal increase in hair shedding amounts following topical minoxidil utilization.

This quiz, the first in 4 part series, focuses on pivotal data from the INTEGUMENT trials in atopic dermatitis.

A Q2 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for dupilumab, pz-cel, ketamine, clesrovimab, and more!

This analysis highlights the increased risk among those with psoriasis for developing such ocular conditions as conjunctivitis, dry eye, and conjunctival hyperemia.

Caution may be needed when prescribing 5 mg of oral minoxidil to patients with alopecia and pericardial risk factors such as systemic lupus erythematosus.

These data highlight the comparability of Humira, the adalimumab originator, to the drug’s biosimilars in terms of efficacy in treating psoriasis.

In this analysis, French investigators highlight patient and clinician perspectives on 1-year use of tildrakizumab for moderate-to-severe psoriasis.

These data highlight the long-term maintenance of bimekizumab responses among individuals with psoriasis, looking at bio-naïve and bio-switched patients.

This interview with Ian Myles, MD, MPH, highlights his team’s recent findings on identifying dermatitis related to topical steroid withdrawal (TSW) versus atopic dermatitis.

These data highlight differences and similarities among dermatologists globally in their decisions related to the treatment of mild-to-moderate atopic dermatitis.

Baricitinib treatment was safe among patients with alopecia areata over 48 weeks in a real-world treatment setting.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode highlights 5 key dermatology updates from the 2025 American Academy of Dermatology Annual Meeting in Orlando.

Investigators highlight systemic treatments for psoriatic disease that maintain lower rates of serious infections among older adults suffering from psoriatic disease.

These recent data demonstrate small doses of doxycycline, an anti-inflammatory medication, may help manage lymphocytic scarring alopecia.